

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 38/03, 38/04, 38/08, 38/10, 38/12, 38/16, C07K 5/00, 5/12, 7/00, 7/64, 11/00, 11/02, 14/00	A1	(11) International Publication Number: WO 97/32594 (43) International Publication Date: 12 September 1997 (12.09.97)
(21) International Application Number: PCT/IL97/00087 (22) International Filing Date: 10 March 1997 (10.03.97) (30) Priority Data: 117426 10 March 1996 (10.03.96) IL (71) Applicant (for all designated States except US): YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HE- BREW UNIVERSITY OF JERUSALEM [IL/IL]; P.O. Box 4279, 91042 Jerusalem (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): BAB, Itai [IL/IL]; 26 Hateena Street, 99797 Carmei Yossef (IL). GAZIT, Dan [IL/IL]; 46 Peretz Bemstein Street, 96920 Jerusalem (IL). YU-CHEN, Chen [CN/CN]; 66/10 Herzl Boulevard, 96141 Jerusalem (IL). MUHLRAD, Andras [IL/IL]; 29/A Neve Shanan Street, 93708 Jerusalem (IL). SHTEYER, Arie [IL/IL]; 37 Haarazim Street, 90805 Mevasseret Zion (IL). CHOREV, Michael [IL/IL]; 135 Fainstein Street, 93812 Jerusalem (IL). (74) Agent: HACKMEY, Michal; A.E. Mulford, P.O. Box 544, 91004 Jerusalem (IL).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. With amended claims.	
(54) Title: SYNTHETIC PEPTIDES AND PSEUDOPEPTIDES HAVING OSTEOGENIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME		
(57) Abstract The invention relates to synthetic pseudopeptide derivatives of osteogenic growth polypeptide (OGP) and OGP (10-14) which may be linear or cyclic, and which are capable of enhancing bone cell proliferation and bone formation. Further, the present invention relates to pharmaceutical composition comprising as active ingredient at least one pseudopeptide derivative of the invention and to the use of these pseudopeptide derivatives in the preparation of a pharmaceutical composition for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation in osteopenic pathological conditions, repairing fractures, healing wounds, grafting of intraosseous implants, reversing bone loss in osteoporosis and other conditions requiring enhanced bone cells formation.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

SYNTHETIC PEPTIDES AND PSEUDOPEPTIDES HAVING OSTEOGENIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

FIELD OF THE INVENTION

- 5 The present invention relates to synthetic pseudopeptide derivatives of OGP and OGP(10-14) which are capable of enhancing bone cell proliferation and bone formation.

BACKGROUND OF THE INVENTION

- 10 It has been established that regenerating bone marrow induces an osteogenic response in distant skeletal sites and that this activity is mediated by factors released into the circulation by the healing tissue [(Bab I., *et al.* (1985) *Calcif. Tissue Int.* 37:551; Foldes, J., *et al.* (1989) *J. Bone Min. Res.* 4:643; Einhorn, T.A., *et al.* (1990) *J. Bone Joint Surg. Am.* 72:1374; Gazit D., *et al.* (1990) *Endocrinology* 126:2607; Mueller, M., *et al.* (1991) *J. Bone Min. Res.* 6:401]. One
15 of these factors, a 14-amino acid osteogenic growth polypeptide (OGP), identical with the C-terminus of histone H4, has been recently identified in the regenerating bone marrow [Bab, I., *et al.* (1992) *EMBO J.* 11:1867; EP-A-0 384 731] and in human serum [Greenberg, Z *et al* (1995) *J. Clin. Endocrinol. Metab* 80:2330].

- 20 Synthetic osteogenic growth polypeptide, identical in structure with the native molecule, has been shown to be a potent stimulator of proliferation of osteoblastic and fibroblastic cells *in vitro*. This synthetic polypeptide also stimulates osteoblastic cell alkaline phosphatase activity. When injected *in vivo* to rats, at very small doses, the synthetic osteogenic growth polypeptide increases bone formation and trabecular bone mass [Bab, I., *et al* (1992) *EMBO J.* 11:1867].


- 25 Since the OGP molecule is too large for effective oral administration, it is of therapeutic importance to identify peptides, shorter than the full length OGP, that retain the OGP activity and can be modified into a stable preparation, suitable for the oral treatment of several pathological conditions, particularly conditions involving loss of bone tissue. Indeed, it was shown that the C-terminal penta-
30 peptide of OGP, Try-Gly-Phe-Gly-Gly[OGP(10-14)], retains the full OGP-like proliferative activity *in vitro* and osteogenic effect *in vivo* [WO94/20529 corresponding to Israel Patent Application No. 104954]. Due to its small size, this

penta-peptide provides a useful basis for the design of further OGP analogs with improved activity, stability and bioavailability.

In search for yet improved osteogenically active substances, the inventors have now found novel, synthetic pseudopeptide derivatives of OGP and OGP(10-14), which are the subject of the present application.

BRIEF DESCRIPTION OF THE INVENTION


The present invention relates to pseudopeptidic osteogenic growth polypeptide (OGP) analogs having the general formula:



(I)

wherein the substituents are as hereafter defined.

The invention also relates to cyclic peptidic or pseudopeptidic OGP analogs having the general formula:



(II)

wherein the substituents are as hereafter defined.

The invention also relates to pharmaceutical compositions comprising as active ingredients the compounds of formulae (I) and/or (II).

DESCRIPTION OF THE FIGURES

Figure 1 shows the linear regression of proliferative activity of OGP between osteoblastic MC3T3E1 and fibroblastic NIH3T3 cells.

Figure 2 shows the dose-response relationship of proliferative activity of cyclic OGP analogs in cultures of osteoblastic MC3T3E1 cells as compared with negative control cultures not treated with any peptide (C) and positive control cultures treated with synthetic OGP(1-14). Data are mean \pm SE obtained in three culture wells per condition.

Figure 3 shows the dose-response relationship of proliferative activity of constrained OGP analogs with substitution of the peptide bond between Leu⁹ and Tyr¹⁰ in cultures of osteoblastic MC3T3E1 (A) and fibroblastic NIH3T3 (B) cells as compared with negative control cultures not treated with any peptide (C) and positive control cultures treated with synthetic OGP(1-14) or OGP(10-14). Data are mean \pm SE obtained in three culture wells per condition.

Figure 4 shows the dose-response relationship of proliferative activity of photoreactive OGP analogs in cultures of osteoblastic MC3T3E1 cells as compared with negative control cultures not treated with any peptide (C) and positive control cultures treated with synthetic OGP(1-14) or OGP(10-14). A-[Bpa¹²]OGP(10-14); B- \pm N α -biotinylcaproyl-[Bpa¹²]OGP(10-14) and positive controls. Data are mean \pm SE obtained in three culture wells per condition.

Figure 5 shows the effect of synthetic OGP analogs on reversal of trabecular bone loss in proximal tibial metaphysis of ovariectomized mice. Data are mean \pm SE obtained in eight mice per group.

Figure 6 shows the effect of OGP analogs on reversal of reduction in osteoprogenitor cells in bone marrow of ovariectomized rats as reflected in number of bone marrow derived *in vitro* osteoblastic colonies. Data are mean \pm SE obtained in five rats per group.

Figure 7 shows the dose-response inhibition of stimulatory effect of optimal OGP(1-14) dose on osteoblastic MC3T3E1 cell as compared with negative control cultures not treated with any peptide (C). All other cultures were


treated with 10^{-13} M synthetic OGP(1-14) and the indicated dose of antagonist. Data are mean \pm SE obtained in three culture wells per condition.

Figure 8 shows the dose-response relationship of anti-proliferative activity of OGP antagonists in cultures of osteoblastic MC3T3E1 cells as compared with negative control cultures not treated with any peptide (C) and positive control cultures treated with synthetic OGP(1-14). Data are mean \pm SE obtained in three culture wells per condition.

DETAILED DESCRIPTION OF THE INVENTION

Osteogenic growth polypeptide (OGP) is a 14-residue polypeptide identified from regenerating bone marrow which has been shown to stimulate the proliferation and alkaline phosphatase activity of osteoblastic and fibroblastic cells *in vitro* and to increase bone formation and trabecular bone mass in rats when injected *in vivo*. In addition, shorter, tetra- and pentapeptides, derived from the C-terminal of OGP have been identified, which retain the OGP activity. Naturally, such short peptides may have advantages as therapeutic agents, being smaller molecules than the native or synthetic full length OGP. The present invention is concerned with various modifications of these peptides, which may be of major interest as potent agonists and antagonists of OGP.

The present invention thus relates to pseudopeptidic osteogenic growth polypeptide (OGP) analogs having the general formula:



wherein

A, B, D and E, which may be the same or different, represent CONH, CH₂NH, CH₂S, CH₂O, NHCO, N(CH₃)CO, (CH₂)₂, CH=CH, C(O)CH₂, CH₂SO or C(O)O,

M represents C(O)OH, CH₂OH, C(O)NH₂, C(O)OCH₃, CH₂OCH₃, H, C(O)NHCH₃, or C(O)N(CH₃)₂,


Z represents NH₂, H, NHCH₃, N(CH₃)₂, OH, SH, OCH₃, SCH₃, C(O)OH, C(O)NH₂, C(O)OCH₃, C(O)NHCH₃ or C(O)N(CH₃)₂,

5 n and m each represent an integer of 1 to 6,

X and Y, if in the ortho or para positions, each represent OH, OCH₃, F, Cl, Br, CF₃, CN, NO₂, NH₂, NHCH₃, N(CH₃)₂, SH, SCH₃, CH₂OH, NHC(O)CH₃, C(O)OH, C(O)OCH₃, C(O)NH₂, C(O)NHCH₃, C(O)N(CH₃)₂, or CH₃, and

10 Y, if in the para or meta positions, represents C(O)C₆H₅, C(O)CH₃, C₆H₅, CH₂C₆H₅, and, if in the ortho or para positions can additionally represent C(O)C₆H₅, C(O)CH₃, C₆H₅, CH₂C₆H₅, CH₂CH₃, CH(CH₃)₂, or C₆H₁₁.

The invention also relates to cyclic peptidic or pseudopeptidic OGP analogs having the general formula:



15

(II)

wherein Z — M represent NHC(O), C(O)NH, CH₂NH, NH₂CH₂, N(CH₃)C(O), C(O)N(CH₃), C(O)O, OC(O), OR (CH₂)_l where l is an integer of from 2 to 6 and A, B, D, E, n, m, X and Y are as hereinbefore defined.

20 A particular pseudopeptidic OGP analog of formula (I) is desaminoTyr-Gly-Phe-Gly-Gly (referred to in the following Examples as desamino[Tyr¹⁰]OGP(10-14)), demonstrating a retention of approximately 70% OGP-like activity (Table 1, analog 4), indicating the minor role of the α-amino group in the OGP activity. Furthermore, *in vivo* effects of this analog (Figure 5,6) were either similar or
 25 superior to the parent oligopeptides, namely, OGP(1-14) and OGP(10-14).

Other particular pseudopeptidic OGP analogs of formula (I) are desaminoTyr-Gly-N(CH₃)-CH(CH₂C₆H₅)-C(O)-Gly-Gly (referred to in the following Examples as desamino[Tyr¹⁰,N(Me)-Phe¹²]OGP(10-14)), desaminoCH(CH₂C₆H₅OH)-CH₂-Gly-Phe-Gly-Gly (referred to in the following Examples as desamino[Tyr¹⁰_ψ(CH₂NH)-Gly¹¹]OGP(10-14)), desaminoTyr-NH-CH₂-CH₂-Phe-Gly-Gly (referred to in the following Examples as desamino[Tyr¹⁰,Gly¹¹_ψ(CH₂NH)Phe¹²]OGP(10-14)), desaminoTyr-Gly-NH-CH(CH₂C₆H₅)-CH₂-Gly-Gly (referred to in the following Examples as desamino[Tyr¹⁰,Phe¹²_ψ(CH₂NH)Gly¹³]OGP(10-14)), desaminoTyr-Gly-Phe-NH-CH₂-CH₂-Gly (referred to in the following Examples as desamino[Tyr¹⁰,Gly¹³_ψ(CH₂NH)Gly¹⁴]OGP(10-14)), desaminoTyr-Gly-Phe-NH-CH₂-CH₂-CH₂-CH₂-C(O)-OH (referred to in the following Examples as desamino[Tyr¹⁰,Gly¹³_ψ(CH₂)₂Gly¹⁴]OGP(10-14)), Tyr-Gly-NH-CH(CH₂C₆H₄-(C(O)-C₆H₅))-C(O)-Gly-Gly (referred to in the following Examples as [Bpa¹²]OGP(10-14)), Tyr(m-I)-Gly-NH-CH(CH₂C₆H₄(C(O)C₆H₅))C(O)-Gly-Gly (referred to in the following Examples as [Tyr¹⁰(m-I),Bpa¹²]OGP(10-14)) and Nα-biotinylcaproyl[Bpa¹²]OGP(10-14), all showing *in vitro* potency, relative to that of OGP, of above 0.5, similar or improved activity compared to desamino[Tyr¹⁰]OGP(10-14) (Tables 5,6)

A particular cyclic peptidic OGP analog of formula (II) is:

20 Tyr—Gly—Phe—Gly—Gly (referred to in the following Examples as c[Tyr-Gly-Phe-Gly-Gly]). This cyclization is another mode to rigidify the OGP(10-14) structure. As can be seen in Figure 2 this rigidification preserves the OGP-like *in vitro* activity. In addition, Figure 6 exhibits an improved *in vivo* activity of c[Tyr-Gly-Phe-Gly-Gly] over OGP(10-14). Also, introduction of D-amino acids into this cyclic peptide, as, for example D-Tyr—Gly—D-Phe—Gly—Gly (referred to in the following Examples as c[D-Tyr-Gly-D-Phe-Gly-Gly]) resulted in a peptide which had a considerable level of proliferative activity.

Other particular cyclic peptidic or pseudopeptidic OGP analogs of formula (II) are:

Gly—Gly—Phe—Gly—Tyr (referred to in the following Examples as c[Gly-Gly-Phe-Gly-Tyr]), and Gly—Gly—D-Phe—Gly—D-Tyr (referred to in the following Examples as c[Gly-Gly-D-Phe-Gly-D-Tyr]) demonstrating a similar or slightly improved *in vitro* activity (Table 5). Interestingly, the retro analog, in which the sequence of the amino acids was reversed, retained a full OGP-like proliferative activity,

suggesting the irrelevance of amide bond direction in the backbone. This observation is also displayed in the constrained, linear pseudopeptides, as shown in Table 5. The improved efficacy of the present constrained analogs might be due to increased resistance to peptidase degradation and longer persistence in circulation or increased potency and bioavailability, as described in the following Examples.

In addition, the invention relates to peptidic and pseudopeptidic osteogenic growth polypeptide antagonists such as, for example, Leu-N(CH₃)-CH(CH₂C₆H₄(OH))-C(O)-Gly-Phe-Gly-Gly ([N(CH₃)-Tyr¹⁰]OGP(9-14)) as herein defined) and Tyr-Gly-Phe-Gly-Asp ([Asp¹⁴]OGP(10-14)) referred to in the following Examples as [N-(CH₃)-Tyr¹⁰]OGP(9-14)). As can be seen in Figure 7, the present antagonists have an inhibitory effect at low doses on stimulation by an optimal OGP(10-14) dose on osteoblastic MC3T3 E1 cells. Moreover, in the absence of exogenous OGP(10-14) the present antagonists demonstrate an anti-proliferative activity in the MC3T3 E1 cells. Nevertheless, a reversal effect is obtained at higher doses, thus showing a dose-dependent response to [N(CH₃)-Tyr¹⁰]OGP(9-14) and [Asp¹⁴]OGP(10-14). These antagonists may be useful in the treatment of conditions characterized by excess OGP.

The invention also relates to pharmaceutical compositions comprising as active ingredient a pseudopeptide of formula (I), optionally with a pharmaceutically acceptable carrier. Particularly preferred are pharmaceutical compositions in which said pseudopeptide is desamino[Tyr¹⁰]OGP(10-14).

A further aspect the invention relates to pharmaceutical compositions comprising as active ingredient a cyclic peptide or pseudopeptide of formula (II), optionally with a pharmaceutically acceptable carrier. Pharmaceutical compositions in which said cyclic peptide is c[Tyr-Gly-Phe-Gly-Gly] are preferred.

The pseudopeptides of formula (I) and cyclic peptides or pseudopeptides of formula (II) may be particularly useful in the preparation of pharmaceutical compositions for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation in osteopenic pathological conditions, repairing fractures, healing wounds, grafting of intraosseous implants, reversing bone loss in osteoporosis and other conditions requiring enhanced bone cells formation.

EXAMPLES

Materials and Methods

General

Boc-amino acids were purchased from either Bachem, California or prepared with di-tert.butyl dicarbonate by conventional procedure [Morodor, L., *et al* (1976) *Physiol. Chem.* 357:1651]. All chemicals were purchased from Aldrich Chemical Co., Fluka Chemie AG or Pierce Chemical Co. and were of analytical grade. Peptidic and pseudopeptidic OGP analogs were treated with liquid HF in an all-Teflon apparatus (Protein Research Foundation, Osaka, Japan). Thin layer chromatography (TLC) was performed on precoated silica gel plates 60F-254 (E. Merck, Darmstadt, FRG) in the following solvent systems (all v/v): (i) 1-BuOH/AcOH/H₂O (4:1:1); (ii) 1-BuOH/AcOH/EtOAc/H₂O (5:1:3:1); (iii) CHCl₃/MeOH/AcOH (9:3:1). Analogs were visualized by UV light and/or ninhydrine staining. Analytical and semipreparative HPLC separations were performed on a Merck Hitachi 655A-11 apparatus, equipped with 655A Variable Wavelength and L-5000 LC Controller, D-2000 Chromato-Integrator and an AS-2000 Autosampler injector. Light absorbance was recorded at 220 nm. A reverse phase Lichrospher 100 C-18 column was used for all analytical applications. The crude OGP analogs were purified on a μ Bondpark C-18, 19X150 mm or a Vydac Protein & Peptide C-18 column employing acetonitrile containing 0.1% (v/v) trifluoroacetic acid in water. Flow rates were 1 ml/min for the analytical column and 6 ml/min for the semipreparative column.

Synthesis of OGP analogs

Unless otherwise indicated, the peptidic or pseudopeptidic OGP analogs of this invention were prepared manually on a Milligen 504 Synthesizer or automatically using a 401A Applied Biosystem Peptide Synthesizer. Boc-Amino acids were assembled on a PAM resin, Merrifield resin, Oxime resin or MBHA resin [Merrifield (1969) *Adv. Enzymol.* 32:221]. The fully assembled analog was removed from the resin either by ammonolysis or the HF procedure.

The preparations were evaluated for purity using analytical HPLC (Vydac C-18 column) and were shown to be more than 95% pure. The molecular weight of the analogs was verified by Fast Atom Bombardment Mass Spectroscopy (FAB-MS). When applicable the analogs were subjected to amino acid analysis.

Introduction of C-terminal modifications

C-terminal modifications were introduced by coupling an active ester with the corresponding amine component either during cleavage from the resin or later in solution [Stewart, J.M., Young, J.D., (1984) In: Solid Phase Peptide Synthesis. 5 Pierce Chemical Co.: Rockford, IL, pp. 1-75].

Preparation of cyclic analogs

N- to C-terminal cyclization was carried out in a low concentration (0.008 M) solution of the corresponding linear peptide in amine-free dimethylformamide (DMF) at 0°C. The coupling agent was diphenol-phosphoryl azide (1.5 equivalent) 10 [Lender, A., *et al* (1993) Int. J. Peptide Protein Res., 42:509]. Upon completion of the reaction the solvent was removed by evaporation and the cyclic analog purified by reverse phase HPLC.

N-terminal to side chain cyclization was carried out with the peptide chain assembled on an Oxime resin. After the removal of the N-terminal protecting group 15 the Oxime resin-bound peptide was subjected to a cyclization-cleavage step [Nishino, N., *et al* (1992) Tetrahedron Letters, 33:1479].

Preparation of analogs with N-methylated Boc-amino acids

The Boc-amino acid used for preparation of the corresponding analogs was dissolved in dry methyl iodide supplemented tetrahydrofuran. N-methylation was 20 induced by NaH. The solvent was removed *in vacuo* and the crude product purified by flash column chromatography eluted with EtOAc-petroleum ether [Cheung, S.T. and Benoiton, N.L., (1977) Can. J. Chem., 55:906].

N-terminal acetylation

Following N-terminal deprotection and prior to cleavage, the resin bound peptide 25 was treated with acetyl hydride and N,N-diisopropylethylamine (DIEA).

Introduction of reduced amide bonds

The introduction of the $\psi(\text{CH}_2\text{NH})$ peptide bond isostere into the corresponding peptides was accomplished by solid phase reaction of the N-terminal amino group of the resin bound peptide with the requisite Boc-protected amino acid aldehyde in 30 the presence of sodium cyanoborohydride in DMF containing 1% AcOH [Sasaki, Y. and Coy, D.H., (1987) Peptides, 8:119]. The corresponding aldehydes were

prepared by LiAlH_4 reduction [Fehrentz, J.-A. and Castro B., (1983) Synthesis, pp. 676-678] of their *N,O*-dimethyl hydroxamates [Hocart, S.J., *et al* (1988) J. Med. Chem. 31:1820].

Preparation of $\text{N}\alpha$ -Biotinylcaproyl-OGP(10-14)

- 5 The purified OGP(10-14) was dissolved in dry DMF containing an equivalent of DIEA and biotin reagent. The reaction mixture was adjusted to pH 8.5 with DIEA. The crude product was neutralized with AcOH and the solvents removed *in vacuo* [Wilchek, M. and Bayer, E.A., (1990) Methods Enzymol 184:5].

Proliferation assay

- 10 The effect of OGP analogs on osteoblastic MC3T3 E1 and fibroblastic NIH 3T3 cell proliferation was measured as before [Bab, I., *et al* (1992) EMBO J. 11:1867]. Some of the analogs were subjected to a dose response analysis. Otherwise the analog concentration was 10^{-13}M and 10^{-11}M in the MC3T3 E1 and NIH3T3 cell cultures, respectively. The mean cell number in triplicate culture wells was
15 expressed as percent of a positive control triplicate dosed with OGP(1-14). Experiments testing one dose per cell line were repeated at least four times and the activity of individual analogs expressed as the mean of results and 95% confidence limit obtained in these repetitive experiments.

Osteogenic effect of OGP analogs in ovariectomized mice

- 20 Thirty two female C57Bl/6 mice weighing 25 gm underwent conventional bilateral ovariectomy (OVX). Additional eight control animals were subjected to sham OVX: the anterior abdominal wall was opened and the ovaries exposed but left intact. All animals were left untreated for 30 days. The OVX animals were then divided into four groups each consisting of eight mice. All animals were injected
25 subcutaneously in the nape daily for six weeks with the following solutions: One group was given OGP(1-14), 30 ng/day/mouse. A second group received OGP(10-14), 10 ng/day/mouse. A third group was given desamino[Tyr¹⁰]OGP(10-14). All compounds were dissolved in phosphate buffered saline (PBS). An additional control OVX group was given the PBS solvent only. One day after termination of
30 treatment the animals were killed and the tibial bones separated, fixed in phosphate buffered formalin and subjected to conventional decalcified histological processing. Sections through the midsagittal region of the tibia were stained with Masson trichrome. Bone volume was determined in the secondary spongiosa of the proximal metaphysis in two sections 200-300 μm apart from each other in one tibia

from each animal using an automated computerized image analyzer. The value for each animal was the mean reading from the two sections.

Effect of OGP analogs on the number of bone marrow derived osteoblastic colonies from ovariectomized rats

5 Twenty five female Sabra rats weighing 250 g each were subjected to bilateral ovariectomy (OVX). Additional five control animals underwent sham OVX. All animals were left untreated for 30 days. Then the OVX animals were divided into five groups, each consisting of five rats. All animals were injected subcutaneously in the nape daily for eight weeks with following solutions: One group was given
10 OGP(10-14), 100 ng/day/rat. A second group was given desamino[Tyr¹⁰]OGP(10-14), 100 ng/day/rat. A third group was given c(Tyr-Gly-Phe-Gly-Gly), 100 ng/day/rat. The fourth group was given retro OGP (Gly-Gly-Phe-Gly-Tyr-Leu-Thr-Arg-Gly-Gln-Arg-Lys-Leu-Ala), 300 ng/day/rat. All compounds were dissolved in PBS. An additional control OVX group was given the PBS solvent
15 only. After termination of treatment the animals were killed and the femoral and tibial bone marrow from both posterior limbs was pooled and transferred to alpha minimal essential medium (α MEM). Bone marrow cell cultures were set in 35 mm dishes, 10 dishes per animal, as described previously [Rickard, D.J., *et al* (1994) *Biology*, 161:218] The total number of fibroblastic colonies (CFU-f) formed was
20 determined after three weeks in culture. Immediately after, the CFU-f cultures were stained for alkaline phosphates and co-stained for mineral with alizarin-red-S. The alizarin-red-S positive colonies were considered osteoblastic. Their frequency was expressed as their percentage of the total numbers of colonies. The value for each animal was calculated as the mean percentage obtained in the 10 dishes.

25 **Results**

The proliferative activity of synthetic OGP analogs is shown in Tables 1-6. There was a very high correlation of the proliferative activity of the analogs between the osteoblastic MC3T3 E1 and fibroblastic NIH3T3 cells (Figure 1). The scatter plot of the MC3T3 E1/ NIH3T3 relationship (Figure 1) demonstrates three clusters of
30 analogs, namely (i) those with activity higher than 50% compared to OGP(1-14); (ii) those showing less than 50% activity compared to OGP(1-14); and (iii) those that inhibit cell proliferation. Only one analog, desamino[Tyr¹⁰]OGP(10-14)-OMe, could not be assigned to one cluster in the sense that it showed slightly more than 50% activity in the MC3T3 E1 cells and less than 50% activity in the NIH3T3 cells
35 (Table 1, analog 8). The activity of few analogs, [Bpa¹²]OGP(10-14) (Table 7,

analog 2), [Tyr¹⁰(m-I), Bpa¹²]OGP(10-14) (Table 7, analog 3), [Pro¹¹]OGP(10-14) (Table 5, analog 2), desamino[Tyr¹⁰ψ(CH₂NH)Gly¹¹]OGP(10-14) (Table 6, analog 2), desamino[Tyr¹⁰,Gly¹³ψ(CH₂NH)Gly¹⁴]OGP(10-14) (Table 6, analog 5), desamino[Tyr¹⁰,Gly¹³ψ(CH₂)₂Gly¹⁴]OGP(10-14) (Table 6, analog 6), c(Tyr-Gly-Phe-Gly-Gly) (Table 5, analog 7), c(Gly-Gly-Phe-Gly-Tyr) (Table 5, analog 9) and c(Gly-Gly-D-Phe-Gly-D-Tyr) (Table 5, analog 11), was similar to that of OGP(1-14) or even higher. The activity of Nα-Ac-OGP(12-14) (Table 1, analog 3), desamino[Tyr¹⁰]OGP(10-13)NH(CH₂)₂OMe (Table 1, analog 12), [Ala¹¹]OGP(11-14) (Table 2, analog 2), [Gly¹³ψ(CH₂)₂Gly¹²]OGP(11-14) (Table 6, analog 7), c(βAla-Tyr-Gly-Phe-Gly-Asp)-OH (Table 5, analog 18) and c(γAbu-Tyr-Gly-Phe-Gly-Asp) (Table 5, analog 19), was essentially nil. Some of the analogs were subjected to a dose-response analysis in the MC3T3E1 and NIH3T3 cell proliferation assays. The resulting biphasic dose-response curve was similar to that of OGP(1-14) and OGP(10-14) [Bab, I., *et al.* (1992) EMBO J. 11:1867; Greenberg, Z., *et al.* (1993) Biochim Biophys Acta 1178:273] with a dose-dependent stimulation at low concentrations followed by a dose-dependent reversal of this stimulation at high doses. The peak response in the MC3T3 E1 and NIH3T3 cells was at 10⁻¹³M and 10⁻¹¹M peptide concentration, respectively (Figures 2-4).

Amino terminal group analysis indicated that the α-amine group has only a small role in the OGP activity as demonstrated by the retention of approximately 70% OGP-like activity by desamino[Tyr¹⁰]OGP(10-14) (Table 1, analog 4). The *in vivo* effects of this analog, namely, the respective reversal of trabecular bone loss and reduction in osteoprogenitor cells in osteoporotic OVX mice and rats, were either similar or superior to those of OGP(1-14) and OGP (10-14) (Figures 5,6) probably because of increased resistance to degradation by amino peptidases. Removal of Tyr¹⁰ (Table 1, analog 2; Table 2, analog 2) or its replacement by L-Ala (Table 2, analog 5), D-Ala (Table 2, analog 5), desaminoAla (Table 2, analog 7), Phe (Table 3, analog 2), desaminoPhe (Table 3, analog 3) or (desaminoPhe)₂ (Table 3, analog 4) resulted in loss of more than 70% activity.

Table 1. Proliferative activity of OGP(10-14) analogs with modified termini

Analog	<u>Relative <i>in vitro</i> potency (95 confidence limit)</u>	
	MC3T3 E1 cells	NIH 3T3 cells
1 OGP(1-14)	1.00 (standard)	1.00 (standard)
2 N α -Ac-OGP(11-14)	0.21(0.17-0.25)	0.22(0.17-0.27)
3 N α -Ac-OGP(12-14)	0.06(0.02-0.11)	0.07(0.03-0.11)
4 desamino[Tyr ¹⁰]OGP(10-14)	0.77(0.66-0.88)	0.66(0.54-0.78)
5 OGP(11-14)-ol	0.24(0.20-0.29)	0.38(0.35-0.42)
6 desamino[Tyr ¹⁰]OGP(10-14)-NH ₂	0.20(0.05-0.35)	0.16(0.05-0.27)
7 desamino[Tyr ¹⁰]OGP(10-14)-ol	0.24(0.14-0.34)	0.28(0.14-0.42)
8 desamino[Tyr ¹⁰]OGP(10-14)-OMe	0.51(0.43-0.59)	0.36(0.29-0.43)
9 desamino[Tyr ¹⁰]OGP(10-14)-NHMe	0.18(0.06-0.30)	0.16(0.08-0.28)
10 desamino[Tyr ¹⁰]OGP(10-14)-N(Me) ₂	0.12(0.08-0.21)	0.16(0.05-0.27)
11 desamino[Tyr ¹⁰]OGP(10-13)-NH(CH ₂) ₂ NH ₂	0.18(0.07-0.29)	0.17(0.06-0.28)
12 desamino[Tyr ¹⁰]OGP(10-13)-NH(CH ₂) ₂ OMe	0.03(0.00-0.06)	0.06(0.01-0.11)
13 desamino[Tyr ¹⁰]OGP(10-13)-NHEt	0.19(0.02-0.36)	0.20(0.11-0.31)

Because of its high *in vitro* and particularly *in vivo* OGP-like activity, the desamino[Tyr¹⁰]OGP(10-14) was used as a basis for carboxy terminal modifications and L- and D-Ala scanning. This analysis shows that at least in a linear structure the intact Gly¹⁴ is essential for a significant level of mitogenic activity inasmuch as all analogs with carboxy terminal group modifications, except maybe desamino[Tyr¹⁰]OGP(10-14)-OMe, lost most the OGP-like activity (Table 1).

The replacement of individual amino acids in both OGP(10-14) and desaminoTyr¹⁰(10-14) by L- or D-Ala or even desamination of Gly¹¹ resulted in all cases in substantial loss of OGP-like proliferative activity (Tables 2,4). These findings further suggest that in both the MC3T3E1 and NIH3T3 cell systems (i) the aromatic ring of Phe¹² is essential for a significant level of OGP-like proliferative activity; (ii) the spatial relationship between the phenolic OH group of Tyr¹⁰ and aromatic ring of Phe¹², including the distance between these groups, may be also

important for this activity. In disagreement with the Ala substitution of Gly¹³ is the replacement of this residue by His which has no consequences upon the activity of OGP(10-14) [WO94/20529 corresponding to Israel Patent Application No. 104954]. Substitution of Gly¹⁴ by Asp resulted in a highly potent OGP antagonist
 5 (Table 3, Figure 7).

Table 2. Proliferative activity of OGP(10-14) analogs with L- or D-Ala substitutions

Analog		<u>Relative <i>in vitro</i> potency (95% confidence limit)</u>	
		MC3T3 E1 cells	NIH 3T3 cells
1	OGP(1-14)	1.00 (standard)	1.00 (standard)
2	[Ala ¹¹]OGP(11-14)	0.17(0.12-0.23)	0.07(0.03-0.12)
3	[Ala ¹³]OGP(11-14)	0.22(0.14-0.29)	0.10(0.05-0.15)
4	[Ala ¹⁴]OGP(11-14)	0.17(0.12-0.23)	0.10(0.06-0.13)
5	[Ala ¹⁰]OGP(10-14)	0.29(0.19-0.39)	0.17(0.04-0.30)
6	[Ala ¹¹]OGP(10-14)	0.18(0.13-0.22)	0.31(0.24-0.37)
7	desamino[Ala ¹⁰]OGP(10-14)	0.28(0.07-0.49)	0.09(0.00-0.18)
8	desamino[Tyr ¹⁰ , Ala ¹¹]OGP(10-14)	0.41(0.29-0.53)	0.43(0.38-0.48)
9	desamino[Tyr ¹⁰ , Ala ¹²]OGP(10-14)	0.21(0.12-0.30)	0.16(0.06-0.26)
10	desamino[Tyr ¹⁰ , Ala ¹³]OGP(10-14)	0.27(0.23-0.31)	0.15(0.09-0.21)
11	desamino[Tyr ¹⁰ , [Ala ¹⁴]OGP(10-14)	0.19(0.04-0.34)	0.16(0.06-0.26)
12	[D-Ala ¹⁰]OGP(10-14)	0.12(0.00-0.25)	0.16(0.05-0.27)
13	[D-Ala ¹³]OGP(10-14)	0.14(0.13-0.16)	0.26(0.20-0.31)
14	desamino[Tyr ¹⁰ , D-Ala ¹¹]OGP(10-14)	0.21(0.00-0.55)	0.19(0.09-0.29)
15	desamino[Tyr ¹⁰ , D-Ala ¹²]OGP(10-14)	0.30(0.13-0.47)	0.02(0.00-0.06)
16	desamino[Tyr ¹⁰ , D-Ala ¹³]OGP(10-14)	0.28(0.19-0.37)	0.23(0.12-0.34)
17	desamino[Tyr ¹⁰ , D-Ala ¹⁴]OGP(10-14)	0.41(0.27-0.55)	0.32(0.17-0.47)

Table 3. Proliferative activity of OGP(10-14) analogs with Phe substitution of Tyr¹⁰

Analog	<u>Relative <i>in vitro</i> potency (95% confidence limit)</u>	
	MC3T3 E1 cells	NIH 3T3 cells
1 OGP(1-14)	1.00 (standard)	1.00 (standard)
2 [Phe ¹⁰]OGP(10-14)	0.41(0.27-0.55)	0.32(0.17-0.47)
3 desamino[Phe ¹⁰]OGP(10-14)	0.35(0.28-0.42)	0.48(0.42-0.54)
4 (desamino[Phe ¹⁰]) ₂ OGP(10-14)	0.18(0.15-0.22)	0.24(0.14-0.33)

Table 4. Proliferative activity of OGP(10-14) analogs with modifications at position 11 and 14

Analog	<u>Relative <i>in vitro</i> potency (95% confidence limit)</u>	
	MC3T3 E1 cells	NIH 3T3 cells
1 OGP(1-14)	1.00 (standard)	1.00 (standard)
2 des[Gly ¹¹]OGP(10-14)	0.21(0.17-0.25)	0.17(0.11-0.23)
3 [β -Ala ¹¹]OGP(10-14)	0.29(0.24-0.34)	0.17(0.13-0.21)
4 [Asp ¹⁴]OGP(10-14)	-0.39(-0.26--0.52)	-0.28(-0.14--0.42)

Most of the structurally constrained OGP analogs show similar or improved activity as compared to the full length OGP. The activity remained essentially unaltered following replacement of Gly¹¹ by Pro (Table 5, analog 2). Rigidification of the OGP(10-14) structure by cyclization also preserved or slightly improved its *in vitro* activity as demonstrated by the analogs c(Tyr-Gly-Phe-Gly-Gly) (Table 5, analog 7), c(Gly-Gly-Phe-Gly-Tyr) (Table 5, analog 9) and c(Gly-Gly-D-Phe-Gly-D-Tyr) (Table 5, analog 11) (Figure 2). c(D-Tyr-Gly-D-Phe-Gly-Gly) (Table 5, analog 10) also retained a considerable level of proliferative activity. In addition, the *in vivo* activity of c(Tyr-Gly-Phe-Gly-Gly) (Table 5, analog 7), i.e. reversal of the OVX induced reduction in bone marrow derived osteoprogenitor cells and osteoblastic colonies, was improved over OGP(10-14) (Figure 6). The introduction of constraints which may alter the Tyr/Phe relationship resulted in less active, or in many instances almost inactive, OGP analogs. Structurally constrained peptide-based drugs usually present improved efficacy as a consequence of their increased (i) resistance to peptidase degradation and longer persistence in the

circulation; (ii) potency and thus improved cellular responsiveness; (iii) bioavailability through non-parenteral routes, e.g. oral.

Table 5. Proliferative activity of constrained OGP analogs

Analog	<u>Relative <i>in vitro</i> potency (95% confidence limit)</u>	
	MC3T3 E1 cells	NIH 3T3 cells
1 OGP(1-14)	1.00 (standard)	1.00 (standard)
2 [Pro ¹¹]OGP(10-14)	0.89(0.80-0.98)	0.96(0.87-1.05)
3 desamino[Tyr ¹⁰ ,Sar ¹¹]OGP(10-14)	0.31(0.25-0.37)	0.39(0.26-0.52)
4 desamino[Tyr ¹⁰ ,N(Me)-Phe ¹²]OGP(10-14)	0.52(0.46-0.58)	0.67(0.55-0.70)
5 desamino[Tyr ¹⁰ ,Sar ¹³]OGP(10-14)	0.15(0.07-0.23)	0.11(0.05-0.17)
6 desamino[Tyr ¹⁰ ,Sar ¹⁴]OGP(10-14)	0.16(0.10-0.22)	0.14(0.09-0.19)
7 c(Tyr-Gly-Phe-Gly-Gly)	0.79(0.72-0.86)	1.12(1.06-1.17)
8 c(Tyr-Gly-Phe-Gly)	0.35(0.30-0.40)	0.43(0.40-0.46)
9 c(Gly-Gly-Phe-Gly-Tyr)	0.95(0.89-1.01)	1.02(0.93-1.11)
10 c(D-Tyr-Gly-D-Phe-Gly-Gly)	0.69(.62-0.76)	0.84(0.80-0.88)
11 c(Gly-Gly-D-Phe-Gly-D-Tyr)	1.03(0.95-1.11)	1.16(1.10-1.22)
12 c(Gly-Tyr-Gly-Phe-Gly-Gly)	0.26(0.19-0.33)	0.20(0.17-0.23)
13 c(β -Ala-Tyr-Gly-Phe-Gly-Gly)	0.36(0.30-0.42)	0.37(0.31-0.43)
14 c(γ -Abu-Tyr-Gly-Phe-Gly-Gly)	0.20(0.16-0.24)	0.22(0.19-0.25)
15 c(δ -Ala-Tyr-Gly-Phe-Gly-Gly)	0.14(0.09-0.19)	0.18(0.13-0.23)
16 c(Tyr-Gly-Phe-Gly-Asp)-OH	0.14(0.09-0.19)	0.11(0.07-0.15)
17 c(Gly-Tyr-Gly-Phe-Gly-Asp)-OH	0.15(0.11-0.19)	0.16(0.12-0.20)
18 c(β -Ala-Tyr-Gly-Phe-Gly-Asp)-OH	-0.08(-0.04--0.12)	-0.19(-0.15--0.23)
19 c(γ -Abu-Tyr-Gly-Phe-Gly-Asp)-OH	0.13(0.10-0.16)	0.07(0.03-0.11)
20 c(δ -Ala-Tyr-Gly-Phe-Gly-Asp)-OH	0.20(0.14-0.26)	0.11(0.09-0.13)

5 The following pseudopeptide analogs of OGP(10-14): desamino[Tyr¹⁰ ψ (CH₂NH)Gly¹¹]OGP(10-14) (Table 6, analog 2), desamino[Tyr¹⁰,Gly¹¹ ψ (CH₂NH)Phe¹²]OGP(10-14) (Table 6, analog 3), desamino[Tyr¹⁰,Phe¹² ψ

(CH₂NH)Gly¹³]OGP(10-14) (Table 6, analog 4), desamino[Tyr¹⁰Gly¹³ψ(CH₂NH)Gly¹⁴]OGP(10-14) (Table 6, analog 5), desamino[Tyr¹⁰Gly¹³ψ(CH₂)₂Gly¹⁴]OGP(10-14) (Table 6, analog 6), had a similar or improved activity compared to desamino[Tyr¹⁰]OGP(10-14) (Table 1, analog 4) also because of increased resistance to peptidase degradation.

Table 6. Proliferative activity of non-constrained pseudopeptide OGP analogs

Analog	<u>Relative <i>in vitro</i> potency (95% confidence limit)</u>	
	MC3T3 E1 cells	NIH 3T3 cells
1 OGP(1-14)	1.00 (standard)	1.00 (standard)
2 desamino[Tyr ¹⁰ ψ(CH ₂ NH)Gly ¹¹]OGP(10-14)	0.81(0.71-0.91)	0.79(0.67-0.91)
3 desamino[Tyr ¹⁰ ,Gly ¹¹ ψ(CH ₂ NH)Phe ¹²]OGP(10-14)	0.61(0.53-0.69)	0.67 (0.60-0.74)
4 desamino[Tyr ¹⁰ ,Phe ¹² ψ(CH ₂ NH)Gly ¹³]OGP(10-14)	0.70(0.65-0.75)	0.88(0.76-1.00)
5 desamino[Tyr ¹⁰ Gly ¹³ ψ(CH ₂ NH)Gly ¹⁴]OGP(10-14)	0.78(0.73-0.83)	0.80(0.67-0.93)
6 desamino[Tyr ¹⁰ Gly ¹³ ψ(CH ₂) ₂ Gly ¹⁴]OGP(10-14)	0.78(0.73-0.83)	0.88(0.79-0.97)
7 [Gly ¹³ ψ(CH ₂) ₂ Gly ¹⁴]OGP(11-14)	0.15(0.11-0.19)	0.08(0.05-0.13)
8 N(Me)-[Tyr ¹⁰]OGP(9-14)	-0.34(-0.19--0.49)	-0.32(-0.27--0.37)
9 N(Me)-[Tyr ¹⁰]OGP(1-14)	0.34(0.27-0.41)	0.42(0.35-0.49)
10 [Leu ⁹ ψ(CH ₂ NH)Tyr ¹⁰]OGP(1-14)	0.45(0.41-0.49)	0.31(0.29-0.33)

Since OGP(10-14) is a naturally occurring peptide [WO94/20529 corresponding to Israel Patent Application No. 104954] the dependence of the OGP(1-14) mitogenic activity on OGP(10-14) formation by proteolysis was assessed using the analogs [N(Me)-Tyr¹⁰]OGP(1-14) (Table 6, analog 9) and [Leu⁹ψ(CH₂NH)Tyr¹⁰]OGP(1-14) (Table 6, analog 10). Either substitution of the natural peptide bond between Leu⁹ and Tyr¹⁰ resulted in more than 50% inhibition of the OGP(1-14) activity (Table 6, Figure 3), suggesting that OGP(10-14) is essential for the full OGP-like activity. However, truncation of the eight N-terminal amino acid residues of one of these analogs yielded another highly potent OGP antagonist, [N(Me)-Tyr¹⁰]OGP(9-14) (Table 6, analog 8) (Figure 7). In the absence of exogenous OGP both antagonists, [N(Me)-Tyr¹⁰]OGP(9-14) and [Asp¹⁴]OGP(10-14), inhibit osteoblastic MC3T3 E1 cell proliferation dose dependently at low concentrations with reversal of this inhibition at high doses. The analog concentration evoking the

peak inhibitory response is 10^{-13} M (Figure 8). The peak stimulatory response to OGP is seen at the same peptide dose [Bab, I., *et al.* (1992) EMBO J. 11:1867; Greenberg, Z., *et al* (1993) Biochim Biophys Acta 1178:273; Greenberg, Z., *et al* (1995) J. Clin. Endocrinol. Metab 80:2330; U.S. Patent No. 5,461,034]. This dose-response pattern suggests that [N(Me)-Tyr¹⁰]OGP(9-14) and [Asp¹⁴]OGP(10-14) antagonize not only the effect of exogenously administered OGP but also the regulatory action of endogenous OGP [Bab, I., *et al.* (1992) EMBO J. 11:1867; Greenberg, Z., *et al* (1995) J. Clin. Endocrinol. Metab 80: 2330] and may therefore be used to neutralize undesirable OGP-like responses particularly in instances characterized by excess endogenous OGP.

A benzoyl was introduced in position 4 of the Phe¹² aromatic ring (Table 7, analog 2) to assess the feasibility of photoaffinity crosslinking of an OGP probe to the putative OGP receptor. This modification had only a minor effect on the OGP-like proliferative activity (Figure 4). This activity remained unaltered following iodination of Tyr¹⁰ or addition of a biotinylcaproyl group to the N-terminal of [Bpa¹²]OGP(10-14) (Table 7, Figure 4), suggesting that either analog, [Tyr¹⁰(m-I),Bpa¹²]OGP(10-14) or N α -biotinylcaproyl-[Bpa¹²]OGP(10-14), is a useful tagged, photoreactive ligand.

Table 7. Proliferative activity of labeled and/or photoreactive OGP(10-14) analogs


Analog	<u>Relative <i>in vitro</i> potency (95% confidence limit)</u>	
	MC3T3 E1 cells	NIH 3T3 cells
1 OGP(1-14)	1.00 (standard)	1.00 (standard)
2 [Bpa ¹²]OGP(10-14)*	0.74(0.66-0.83)	0.86(0.75-0.97)
3 [Tyr ¹⁰ (m-I),Bpa ¹²]OGP(10-14)	0.80(0.74-0.86)	0.85(0.76-0.94)
4 N α -biotinylcaproyl-[Bpa ¹²]OGP(10-14) *		

• See Figure 4 for dose response curve.

••Tested once in triplicate culture wells - see Figure 4 for dose response curve.

CLAIMS:

1. Pseudopeptidic osteogenic growth polypeptide (OGP) analogs having the general formula:



(I)

wherein

D and E, which may be the same or different, represent CONH, CH₂NH, CH₂S, CH₂O, NHCO, N(CH₃)CO, (CH₂)₂, CH=CH, C(O)CH₂, CH₂SO or C(O)O,

- 10 M represents C(O)OH, CH₂OH, C(O)NH₂, C(O)OCH₃, CH₂OCH₃, H, C(O)NHCH₃, or C(O)N(CH₃)₂,


Z represents NH₂, H, NHCH₃, N(CH₃)₂, OH, SH, OCH₃, SCH₃, C(O)OH, C(O)NH₂, C(O)OCH₃, C(O)NHCH₃ or C(O)N(CH₃)₂,

n and m each represent an integer of from 1 to 6,

- 15 X and Y, if in the ortho or para positions, each represent OH, OCH₃, F, Cl, Br, CF₃, CN, NO₂, NH₂, NHCH₃, N(CH₃)₂, SH, SCH₃, CH₂OH, NHC(O)CH₃, C(O)OH, C(O)OCH₃, C(O)NH₂, C(O)NHCH₃, C(O)N(CH₃)₂, or CH₃, and

- if in the para or meta positions, represents C(O)C₆H₅, C(O)CH₃, C₆H₅, CH₂C₆H₅, and, if in the ortho or para positions can additionally represent
 20 C(O)C₆H₅, C(O)CH₃, C₆H₅, CH₂C₆H₅, CH₂CH₃, CH(CH₃)₂, or C₆H₁₁.

2. Pseudopeptidic OGP analogs having the general formula:



wherein Z—M represent NHC(O) , C(O)NH , CH_2NH , NH_2CH_2 , $\text{N(CH}_3\text{)C(O)}$, $\text{C(O)N(CH}_3\text{)}$, C(O)O , OC(O) , OR $(\text{CH}_2)_1$ where 1 is an integer of from 2 to 6 and A, B, D, E, n, m, X and Y are as defined in claim 1.

- 5 3. A pseudo-peptidic OGP analog according to claim 1 being:

desaminoTyr-Gly-Phe-Gly-Gly (desamino[Tyr¹⁰]OGP(10-14) as hereinbefore defined), desaminoTyr-Gly-N(CH₃)-CH(CH₂C₆H₅)-C(O)-Gly-Gly (desamino[Tyr¹⁰,N(Me)-Phe¹²]OGP(10-14) as hereinbefore defined), desaminoCH(CH₂C₆H₅OH)-CH₂-Gly-Phe-Gly-Gly (desamino[Tyr¹⁰ψ
10 (CH₂NH)Gly]OGP(10-14) as hereinbefore defined), desaminoTyr-NH-CH₂-CH₂-Phe-Gly-Gly, (desamino[Tyr¹⁰,Gly¹¹ψ(CH₂NH)Phe¹²]OGP(10-14) as hereinbefore defined), desaminoTyr-Gly-NH-CH(CH₂C₆H₅)-CH₂-Gly-Gly (desamino[Tyr¹⁰,Phe¹²ψ(CH₂NH)-Gly¹³]OGP(10-14) as hereinbefore defined), desaminoTyr-Gly-Phe-NH-CH₂-CH₂-Gly (desamino[Tyr¹⁰,Gly¹³ψ
15 (CH₂NH)Gly¹⁴]OGP(10-14) as hereinbefore defined), desaminoTyr-Gly-Phe-NH-CH₂-CH₂-CH₂-CH₂-C(O)-OH (desamino[Tyr¹⁰,Gly¹³ψ (CH₂)₂Gly¹⁴]OGP(10-14) as hereinbefore defined), Tyr-Gly-NH-CH(CH₂C₆H₄-(C(O)-C₆H₅))-C(O)-Gly-Gly ([Bpa¹²] OGP(10-14) as hereinbefore defined), Tyr(m-I)-Gly-NH-CH(CH₂C₆H₄(C(O)C₆H₅))C(O)-
20 Gly-Gly ([Tyr(m-I),Bpa¹²]OGP(10-14) as hereinbefore defined) or Nα-biotinylcaproyl-[Bpa¹²]OGP(10-14) as hereinbefore defined.

4. A peptidic or pseudo-peptidic OGP analog according to claim 2 being:

Tyr—Gly—Phe—Gly—Gly
 [] (c[Tyr-Gly-Phe-Gly-Gly] as herein before defined),
 Gly—Gly—Phe—Gly—Tyr
 [] (c[Gly-Gly-Phe-Gly-Tyr] as hereinbefore defined),
 D-Tyr—Gly—D-Phe—Gly—Gly
 [] (c[D-Tyr-Gly-D-Phe-Gly-Gly] as hereinbefore
 25 defined) or Gly—Gly—D-Phe—Gly—D-Tyr
 [] (c[Gly-Gly-D-Phe-Gly-D-Tyr] as
 hereinbefore defined).


SUBSTITUTE SHEET (RULE 26)

5. Pseudopeptidic osteogenic growth factor antagonists being Leu-N(CH₃)-CH(CH₂C₆H₄(OH))-C(O)-Gly-Phe-Gly-Gly ([N(CH₃)Tyr¹⁰]OGP(9-14) as hereinbefore defined) and Tyr-Gly-Phe-Gly-Asp ([Asp¹⁴]OGP(10-14) as hereinbefore defined).
- 5 6. Pharmaceutical composition comprising as active ingredient at least one pseudopeptide of formula (I), optionally with a pharmaceutically acceptable carrier.
7. Pharmaceutical composition according to claim 6 wherein said pseudopeptide is desamino[Tyr¹⁰]OGP(10-14).
- 10 8. Pharmaceutical composition comprising as active ingredient at least one cyclic peptide or pseudopeptide of formula (II), optionally with a pharmaceutically acceptable carrier.
9. Pharmaceutical composition according to claim 8 wherein said cyclic peptide is c[Tyr-Gly-Phe-Gly-Gly].
- 15 10. Pharmaceutical composition comprising as active ingredient at least one pseudopeptide of formula (I) and at least one cyclic peptide or pseudopeptide of formula (II), optionally with a pharmaceutically acceptable carrier.
- 20 11. A pseudopeptide according to claim 1 or claim 3 for use in the preparation of a pharmaceutical composition for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation in osteopenic pathological conditions, repairing fractures, healing wounds, grafting of intraosseous implants, reversing bone loss in osteoporosis and other conditions requiring enhanced bone cells formation.
- 25 12. A cyclic peptide or pseudopeptide according to claim 2 or claim 4 for use in the preparation of a pharmaceutical composition for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation in osteopenic pathological conditions, repairing fractures, healing wounds, grafting of intraosseous implants, reversing bone loss in osteoporosis and other conditions requiring enhanced bone cells formation.

AMENDED CLAIMS

[received by the International Bureau on 28 July 1997 (28.07.97);
original claims 1 and 2 amended; remaining claims unchanged (3 pages)]

1. Pseudopeptidic osteogenic growth polypeptide (OGP) analogs having the general formula:



wherein

A, B, D and E, which may be the same or different, represent CONH, CH₂NH, CH₂S, CH₂O, NHCO, N(CH₃)CO, (CH₂)₂, CH=CH, C(O)CH₂, CH₂SO or C(O)O,

M represents C(O)OH, CH₂OH, C(O)NH₂, C(O)OCH₃, CH₂OCH₃, H, C(O)NHCH₃, or C(O)N(CH₃)₂,

Z represents NH₂, H, NHCH₃, N(CH₃)₂, OH, SH, OCH₃, SCH₃, C(O)OH, C(O)NH₂, C(O)OCH₃, C(O)NHCH₃ or C(O)N(CH₃)₂,

n and m each represent an integer of from 1 to 6,


X and Y, if in the ortho or para positions, each represent OH, OCH₃, F, Cl, Br, CF₃, CN, NO₂, NH₂, NHCH₃, N(CH₃)₂, SH, SCH₃, CH₂OH, NHC(O)CH₃, C(O)OH, C(O)OCH₃, C(O)NH₂, C(O)NHCH₃, C(O)N(CH₃)₂, or CH₃, and

if in the para or meta positions, represents C(O)C₆H₅, C(O)CH₃, C₆H₅, CH₂C₆H₅, and, if in the ortho or para positions can additionally represent C(O)C₆H₅, C(O)CH₃, C₆H₅, CH₂C₆H₅, CH₂CH₃, CH(CH₃)₂, or C₆H₁₁.

2. Pseudopeptidic OGP analogs having the general formula:

AMENDED SHEET (ARTICLE 19)

23




wherein Z—M represent NHC(O), C(O)NH, CH₂NH, NH₂CH₂, N(CH₃)C(O), C(O)N(CH₃), C(O)O, OC(O), OR (CH₂)₁ where 1 is an integer of from 2 to 6 and A, B, D, E, n, m, X and Y are as defined in claim 1.

3. A pseudopeptidic OGP analog according to claim 1 being:

desaminoTyr-Gly-Phe-Gly-Gly (desamino[Tyr¹⁰]OGP(10-14) as hereinbefore defined), desaminoTyr-Gly-N(CH₃)-CH(CH₂C₆H₅)-C(O)-Gly-Gly (desamino[Tyr¹⁰,N(Me)-Phe¹²]OGP(10-14) as hereinbefore defined),
 10 desaminoCH(CH₂C₆H₅OH)-CH₂-Gly-Phe-Gly-Gly (desamino[Tyr¹⁰ψ(CH₂NH)Gly]OGP(10-14) as hereinbefore defined), desaminoTyr-NH-CH₂-CH₂-Phe-Gly-Gly, (desamino[Tyr¹⁰,Gly¹¹ψ(CH₂NH)Phe¹²]OGP(10-14) as hereinbefore defined), desaminoTyr-Gly-NH-CH(CH₂C₆H₅)-CH₂-Gly-Gly (desamino[Tyr¹⁰,Phe¹²ψ(CH₂NH)-Gly¹³]OGP(10-14) as hereinbefore defined),
 15 desaminoTyr-Gly-Phe-NH-CH₂-CH₂-Gly (desamino[Tyr¹⁰,Gly¹³ψ(CH₂NH)Gly¹⁴]OGP(10-14) as hereinbefore defined), desaminoTyr-Gly-Phe-NH-CH₂-CH₂-CH₂-CH₂-C(O)-OH (desamino[Tyr¹⁰,Gly¹³ψ(CH₂)₂Gly¹⁴]OGP(10-14) as hereinbefore defined), Tyr-Gly-NH-CH(CH₂C₆H₄-(C(O)-C₆H₅))-C(O)-Gly-Gly ([Bpa¹²] OGP(10-14) as hereinbefore defined), Tyr(m-I)-Gly-NH-CH(CH₂C₆H₄(C(O)C₆H₅))C(O)-Gly-Gly ([Tyr(m-I),Bpa¹²]OGP(10-14) as hereinbefore defined) or Nα-biotinylcaproyl-[Bpa¹²]OGP(10-14) as hereinbefore defined.

4. A peptidic or pseudopeptidic OGP analog according to claim 2 being:



AMENDED SHEET (ARTICLE 19)

defined) or $\text{Gly-Gly-D-Phe-Gly-D-Tyr}$ (c[Gly-Gly-D-Phe-Gly-D-Tyr] as hereinbefore defined).

5. Pseudopeptidic osteogenic growth factor antagonists being Leu-N(CH₃)-CH(CH₂C₆H₄(OH))-C(O)-Gly-Phe-Gly-Gly ([N(CH₃)Tyr¹⁰]OGP(9-14) as hereinbefore defined) and Tyr-Gly-Phe-Gly-Asp ([Asp¹⁴]OGP(10-14) as hereinbefore defined).
6. Pharmaceutical composition comprising as active ingredient at least one pseudopeptide of formula (I), optionally with a pharmaceutically acceptable carrier.
7. Pharmaceutical composition according to claim 6 wherein said pseudopeptide is desamino[Tyr¹⁰]OGP(10-14).
8. Pharmaceutical composition comprising as active ingredient at least one cyclic peptide or pseudopeptide of formula (II), optionally with a pharmaceutically acceptable carrier.
9. Pharmaceutical composition according to claim 8 wherein said cyclic peptide is c[Tyr-Gly-Phe-Gly-Gly].
10. Pharmaceutical composition comprising as active ingredient at least one pseudopeptide of formula (I) and at least one cyclic peptide or pseudopeptide of formula (II), optionally with a pharmaceutically acceptable carrier.
11. A pseudopeptide according to claim 1 or claim 3 for use in the preparation of a pharmaceutical composition for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation in osteopenic pathological conditions, repairing fractures, healing wounds, grafting of intraosseous implants, reversing bone loss in osteoporosis and other conditions requiring enhanced bone cells formation.
12. A cyclic peptide or pseudopeptide according to claim 2 or claim 4 for use in the preparation of a pharmaceutical composition for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation in osteopenic pathological conditions, repairing fractures, healing wounds, grafting of intraosseous implants, reversing bone loss in osteoporosis and other conditions requiring enhanced bone cells formation.

AMENDED SHEET (ARTICLE 19)

1/8







Figure 1
SUBSTITUTE SHEET (RULE 26)

2/8

**Figure 2**

SUBSTITUTE SHEET (RULE 26)

**Figure 3A****Figure 3B**

SUBSTITUTE SHEET (RULE 26)




Figure 4A






Figure 4B

SUBSTITUTE SHEET (RULE 26)


5/8

**Figure 5**

6/8


**Figure 6**

7/8

**Figure 7**

SUBSTITUTE SHEET (RULE 26)

8/8

**Figure 8**

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IL97/00087

A. CLASSIFICATION OF SUBJECT MATTER																				
IPC(6) : Please See Extra Sheet.																				
US CL : Please See Extra Sheet.																				
According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED																				
Minimum documentation searched (classification system followed by classification symbols)																				
U.S. : 514/2, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18; 530/300, 317, 324, 325, 326, 327, 328, 329, 330, 350, 402																				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																				
APS, DIALOG (Biotech Files), GenEMBL sequence databases, STN																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
A	EP 0 572 122 A2 (YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM) 01 December 1993, see entire document.	3-5, 7, 9																		
A	WO 94/20529 A1 (YISSUM RESEARCH AND DEVELOPMENT COMPANY) 15 September 1994, see entire document.	3-5, 7, 9																		
A	BAB et al. Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity. The EMBO Journal. 1992, Vol. 11, No. 5, pages 1867-1873, see entire document.	3-5, 7, 9																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>* T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>* A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>* X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>* E* earlier document published on or after the international filing date</td> <td>* Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>* L* document which may throw doubts on priority claims) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>* &*</td> <td>document member of the same patent family</td> </tr> <tr> <td>* O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>* P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	* A* document defining the general state of the art which is not considered to be of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	* L* document which may throw doubts on priority claims) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &*	document member of the same patent family	* O* document referring to an oral disclosure, use, exhibition or other means			* P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
* A* document defining the general state of the art which is not considered to be of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
* L* document which may throw doubts on priority claims) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &*	document member of the same patent family																		
* O* document referring to an oral disclosure, use, exhibition or other means																				
* P* document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search		Date of mailing of the international search report																		
23 JUNE 1997		09 JUL 1997																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized officer																		
Facsimile No. (703) 305-3230		ELIZABETH C. KEMMERER																		
		Telephone No. (703) 308-0196																		

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IL97/00087

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GREENBERG et al. Mitogenic action of osteogenic growth peptide (OGP): role of amino and carboxy-terminal regions and charge. Biochimica et Biophysica Acta. 1993, Vol. 1178, pages 273-280, see entire document.	3-5, 7, 9
A	GREENBERG et al. Structural and Functional Characterization of Osteogenic Growth Peptide from Human Serum: Identity with Rat and Mouse Homologs. Journal of Clinical Endocrinology and Metabolism. Vol. 80, No. 8, 1995, pages 2330-2335, see entire document.	3-5, 7, 9

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IL97/00087

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1, 2, 6, 8, and 10-12
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

There is no "m" in formula (I) or (II). Also, "A" and "B" appearing in formulas (I) and (II) are not defined in the claims.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IL97/00087

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A61K 38/03, 38/04, 38/08, 38/10, 38/12, 38/16; C07K 5/00, 5/12, 7/00, 7/64, 11/00, 11/02, 14/00

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

514/2, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18; 530/300, 317, 324, 325, 326, 327, 328, 329, 330, 350, 402